{"id":11988,"date":"2026-11-09T10:00:00","date_gmt":"2026-11-09T09:00:00","guid":{"rendered":"https:\/\/www.medespoir.ch\/blog\/?p=11988"},"modified":"2026-11-08T16:07:47","modified_gmt":"2026-11-08T15:07:47","slug":"type-2-diabetes-metabolic-surgery-switzerland","status":"publish","type":"post","link":"https:\/\/www.medespoir.ch\/blog\/type-2-diabetes-metabolic-surgery-switzerland\/","title":{"rendered":"Type 2 diabetes and weight-loss surgery in Switzerland: can metabolic surgery bring remission?"},"content":{"rendered":"<p><strong>In short:<\/strong> for people with type 2 diabetes and obesity, bariatric surgery is also a diabetes treatment, which is why specialists call it metabolic surgery. Randomised trials followed for up to twelve years show better blood sugar control, fewer medicines and more frequent remission after a sleeve gastrectomy or a gastric bypass than with medical treatment alone, although diabetes returns in a share of patients over time. Remission has a precise definition: an HbA1c below 6.5% (48 mmol\/mol) at least three months after stopping all glucose-lowering medicines. In Switzerland, basic insurance (KVG\/LAMal) covers the operation with a BMI of 35 or more after two years of unsuccessful treatment, and the SMOB guidelines allow a narrow exception between 30 and 35 for diabetes that remains poorly controlled despite optimal specialist care. This guide explains who benefits most, how medicines and glucose monitoring are managed around surgery, and what follow-up is needed for life.<\/p>\n<p><em>This article is general information. It does not replace advice from your diabetologist, surgeon or family doctor. Never change your diabetes medicines without medical advice.<\/em><\/p>\n<p>For the choice between the different operations, see our guide <a href=\"https:\/\/www.medespoir.ch\/blog\/choosing-bariatric-surgery-switzerland-sleeve-bypass\/\">Sleeve, bypass, band or balloon: how do you choose?<\/a>, and for everyday life after surgery, <a href=\"https:\/\/www.medespoir.ch\/blog\/life-after-bariatric-surgery-switzerland\/\">Life after bariatric surgery in Switzerland<\/a>. This article is devoted to type 2 diabetes.<\/p>\n<h2 id=\"contents\">Contents<\/h2>\n<ul>\n<li><a href=\"#news\">What is new in 2025 and 2026<\/a><\/li>\n<li><a href=\"#how\">How surgery acts on diabetes<\/a><\/li>\n<li><a href=\"#remission\">What \u00ab\u00a0remission\u00a0\u00bb really means<\/a><\/li>\n<li><a href=\"#evidence\">What the long-term studies show<\/a><\/li>\n<li><a href=\"#who\">Who benefits most?<\/a><\/li>\n<li><a href=\"#criteria\">Eligibility: international and Swiss criteria<\/a><\/li>\n<li><a href=\"#operation\">Sleeve or bypass when you have diabetes<\/a><\/li>\n<li><a href=\"#before\">Before surgery: tests and medicines<\/a><\/li>\n<li><a href=\"#after\">After surgery: glucose monitoring and medicines<\/a><\/li>\n<li><a href=\"#hypo\">Low blood sugar after a bypass<\/a><\/li>\n<li><a href=\"#everyday\">Everyday questions in the first year<\/a><\/li>\n<li><a href=\"#longterm\">Follow-up for life and the risk of relapse<\/a><\/li>\n<li><a href=\"#glp1\">GLP-1 medicines or surgery?<\/a><\/li>\n<li><a href=\"#abroad\">Insurance, Switzerland or abroad<\/a><\/li>\n<li><a href=\"#faq\">FAQ<\/a><\/li>\n<\/ul>\n<h2 id=\"news\">What is new in 2025 and 2026<\/h2>\n<h3>A Swiss obesity guidance places surgery in a long-term pathway<\/h3>\n<p>On 19 May 2026, Swiss Medical Weekly published the Swiss obesity clinical practice guidance (Gerber PA et al.), written with the Swiss Society of Endocrinology and Diabetology and other societies. It describes obesity as a chronic, relapsing disease, recommends looking beyond BMI at complications such as diabetes, and treats lifestyle measures, incretin-based medicines and bariatric and metabolic surgery as steps in one long-term pathway. Surgery is reserved for severe or treatment-resistant obesity and requires lifelong interdisciplinary follow-up.<\/p>\n<h3>Mounjaro joined Wegovy on the reimbursed list<\/h3>\n<p>According to a position paper of the Swiss Association of Dietitians (SVDE) and the Swiss Obesity Alliance (ALLOB) dated 31 January 2026, Wegovy (semaglutide) has been reimbursed for weight management since 1 March 2024 and Mounjaro (tirzepatide) since 1 January 2026. The University Hospital Zurich summarises the conditions on its patient page, updated on 22 October 2026: a BMI above 35, or above 28 with a related condition such as type 2 diabetes, prediabetes, high blood pressure or abnormal blood lipids, a prescription by a specialist or obesity centre, individual weight targets and initial coverage for three years. For people with diabetes, this means a real medical alternative or a step before surgery.<\/p>\n<h3>The 2026 benefits list confirms the surgery rules<\/h3>\n<p>The edition of Annex 1 of the health care benefits ordinance (KLV\/OPAS) dated 1 July 2026 confirms that basic insurance covers surgical treatment of obesity with a BMI above 35 after two years of adequate, unsuccessful weight-reduction treatment, with indication, surgery and follow-up according to the guidelines of the Swiss Society for the Study of Morbid Obesity and Metabolic Disorders (SMOB).<\/p>\n<h3>Surgery and the new medicines compared in diabetes<\/h3>\n<p>A large US study published in 2026 in <em>The Lancet Diabetes &amp; Endocrinology<\/em> (Leslie D et al.) compared adults with a BMI of at least 35 and type 2 diabetes treated with a sleeve gastrectomy, tirzepatide or semaglutide. After one year, the adjusted probability of reaching both 20% weight loss and near-normal blood sugar was 24.0% after sleeve gastrectomy, 13.2% with tirzepatide and 3.0% with semaglutide. Emergency visits were more frequent after surgery, and the study is observational, so it cannot prove cause and effect. It nevertheless reflects what diabetologists observe: surgery remains the most powerful tool for many patients, but not the only one.<\/p>\n<table>\n<thead>\n<tr>\n<th>Date<\/th>\n<th>Source<\/th>\n<th>Key point<\/th>\n<th>What it means for you<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>1 Jan. 2026<\/td>\n<td>Swiss reimbursement list (SVDE\/ALLOB)<\/td>\n<td>Mounjaro reimbursed under conditions, like Wegovy<\/td>\n<td>A medical option to discuss before or instead of surgery<\/td>\n<\/tr>\n<tr>\n<td>19 May 2026<\/td>\n<td>Swiss Medical Weekly, national guidance<\/td>\n<td>Lifestyle, medicines and surgery in one pathway<\/td>\n<td>Expect your team to discuss all options<\/td>\n<\/tr>\n<tr>\n<td>1 July 2026<\/td>\n<td>KLV\/OPAS Annex 1<\/td>\n<td>Surgery covered with BMI above 35 and two years of failed treatment<\/td>\n<td>The SMOB rules apply, including for diabetes<\/td>\n<\/tr>\n<tr>\n<td>2026<\/td>\n<td>Leslie D et al., Lancet Diabetes &amp; Endocrinology<\/td>\n<td>More patients reached weight and glucose targets after sleeve than with injections<\/td>\n<td>Observational data; individual choice remains essential<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h2 id=\"how\">How surgery acts on diabetes<\/h2>\n<p>Many people notice that their blood sugar improves within days after surgery, long before they have lost much weight. This early effect is one of the reasons why surgeons and diabetologists speak of metabolic surgery.<\/p>\n<h3>Why does blood sugar improve so quickly?<\/h3>\n<p>Several mechanisms combine. Immediately after surgery, food intake is very low, which reduces the load on the pancreas and the liver. The liver&rsquo;s fat content falls, and the liver becomes more sensitive to insulin. After a gastric bypass, and to a lesser extent after a sleeve, food reaches the small intestine faster, which increases the release of gut hormones such as GLP-1, the same hormone imitated by medicines like semaglutide. Changes in bile acids and gut bacteria are also studied. Over the following months, weight loss improves the body&rsquo;s response to insulin.<\/p>\n<h3>Does surgery cure diabetes?<\/h3>\n<p>Specialists avoid the word \u00ab\u00a0cure\u00a0\u00bb. Type 2 diabetes reflects both insulin resistance and a decline in the pancreas&rsquo;s ability to produce insulin. Surgery can greatly reduce insulin resistance, but it cannot restore insulin-producing cells that have been lost over many years. That is why results depend so much on how long you have had diabetes and how much insulin your pancreas still makes.<\/p>\n<h3>Does it work for type 1 diabetes?<\/h3>\n<p>No. Type 1 diabetes is caused by the destruction of insulin-producing cells by the immune system, and insulin remains indispensable after any operation. People with type 1 diabetes and severe obesity can sometimes benefit from surgery for their weight and other conditions, but in specialised centres and with very close insulin management.<\/p>\n<h2 id=\"remission\">What \u00ab\u00a0remission\u00a0\u00bb really means<\/h2>\n<h3>How is remission defined?<\/h3>\n<p>In 2021, a consensus report by the American Diabetes Association, the European Association for the Study of Diabetes, Diabetes UK and other experts, published in <em>Diabetes Care<\/em> (Riddle MC et al.), proposed a common definition: remission is an HbA1c below 6.5% (48 mmol\/mol) measured at least three months after stopping all glucose-lowering medicines. The authors chose \u00ab\u00a0remission\u00a0\u00bb rather than \u00ab\u00a0cure\u00a0\u00bb precisely because the diabetes can return.<\/p>\n<h3>Why do studies report such different remission rates?<\/h3>\n<p>Because they use different definitions (partial, complete, with or without medicines), different follow-up times and different patients. Some studies count HbA1c below 6.0%, others below 6.5%; some measure at one year, others at fifteen. A figure of \u00ab\u00a080% remission\u00a0\u00bb from a short study and \u00ab\u00a020% remission\u00a0\u00bb from a long one can both be correct. Always ask: which definition, after how long, in which patients?<\/p>\n<h3>If I am in remission, do I still need check-ups?<\/h3>\n<p>Yes. The consensus recommends continuing to measure HbA1c at least once a year, and specialists recommend continuing screening for complications, especially the eyes, kidneys and feet, because damage that occurred before surgery does not disappear and diabetes can return.<\/p>\n<h2 id=\"evidence\">What the long-term studies show<\/h2>\n<p>Metabolic surgery is one of the best-studied treatments of type 2 diabetes, with randomised trials and very long observational studies.<\/p>\n<h3>STAMPEDE: five years of randomised data<\/h3>\n<p>In the STAMPEDE trial, published in the <em>New England Journal of Medicine<\/em> in February 2017, 150 patients with type 2 diabetes and a BMI between 27 and 43 were randomised to intensive medical therapy alone or combined with a gastric bypass or a sleeve gastrectomy. At five years, an HbA1c of 6.0% or less, with or without medicines, was reached by 5% of patients with medical therapy alone, 29% after gastric bypass and 23% after sleeve gastrectomy. Surgical patients also needed less insulin and reported better quality of life.<\/p>\n<h3>ARMMS-T2D: up to twelve years<\/h3>\n<p>The ARMMS-T2D analysis, published in <em>JAMA<\/em> on 27 February 2024, pooled four randomised trials with 262 participants and a median follow-up of 11 years. At seven years, HbA1c had fallen by 1.6 percentage points after surgery against 0.2 with medical and lifestyle management. Diabetes remission was 18.2% after surgery against 6.2% at seven years, and 12.7% against 0.0% at twelve years. Surgical patients used fewer diabetes medicines, but anaemia, fractures and digestive side effects were more common.<\/p>\n<h3>Swedish Obese Subjects: fifteen years and complications<\/h3>\n<p>The Swedish Obese Subjects study, published in <em>JAMA<\/em> in June 2014, compared surgical patients with matched controls receiving usual care. Two years after surgery, diabetes remission was 72.3% in the surgery group against 16.4% in controls; at fifteen years, 30.4% against 6.5%. Over the long term, microvascular complications (eyes, kidneys, nerves) were about half as frequent after surgery, and macrovascular complications (heart attack, stroke) were also less frequent. Because this study was not randomised, the results require caution, but they show that benefits persist even when diabetes returns.<\/p>\n<h3>SLEEVEPASS and SM-BOSS: sleeve against bypass<\/h3>\n<p>Two randomised trials compared the two main operations. In the Finnish SLEEVEPASS trial (<em>JAMA<\/em>, January 2018), complete or partial remission of type 2 diabetes at five years was seen in 37% of patients after sleeve gastrectomy and 45% after gastric bypass, a difference that was not statistically significant. The Swiss SM-BOSS trial, published in the same issue, found no significant difference in excess BMI loss at five years, but reflux improved much more often after bypass (60.4%) than after sleeve (25.0%), and worsened more often after sleeve.<\/p>\n<table>\n<thead>\n<tr>\n<th>Study<\/th>\n<th>Design<\/th>\n<th>Follow-up<\/th>\n<th>Main diabetes result<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>STAMPEDE (NEJM 2017)<\/td>\n<td>Randomised, 150 patients, BMI 27 to 43<\/td>\n<td>5 years<\/td>\n<td>HbA1c 6.0% or less: 29% bypass, 23% sleeve, 5% medical<\/td>\n<\/tr>\n<tr>\n<td>ARMMS-T2D (JAMA 2024)<\/td>\n<td>Pooled randomised trials, 262 patients<\/td>\n<td>Median 11 years<\/td>\n<td>Remission 18.2% vs 6.2% at 7 years; 12.7% vs 0.0% at 12 years<\/td>\n<\/tr>\n<tr>\n<td>Swedish Obese Subjects (JAMA 2014)<\/td>\n<td>Observational, matched controls<\/td>\n<td>15 years<\/td>\n<td>Remission 72.3% vs 16.4% at 2 years; 30.4% vs 6.5% at 15 years; fewer complications<\/td>\n<\/tr>\n<tr>\n<td>SLEEVEPASS (JAMA 2018)<\/td>\n<td>Randomised, sleeve vs bypass<\/td>\n<td>5 years<\/td>\n<td>Remission 37% after sleeve, 45% after bypass (not significant)<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h2 id=\"who\">Who benefits most?<\/h2>\n<h3>Which factors predict remission?<\/h3>\n<p>The most consistent predictors are a short duration of diabetes, no insulin treatment before surgery, a lower HbA1c, fewer diabetes medicines and a younger age. The DiaRem score, published in 2014 in <em>The Lancet Diabetes &amp; Endocrinology<\/em>, combines insulin use, age, HbA1c and the type of medicines, with insulin use carrying the greatest weight. In the original group of gastric bypass patients, early remission was reached by 88% of those with the lowest scores and by 2% of those with the highest. Such scores help to set expectations; they do not decide whether you should have surgery.<\/p>\n<h3>Is surgery still worthwhile if I have had diabetes for fifteen years and use insulin?<\/h3>\n<p>Remission is less likely, but surgery can still reduce insulin doses, improve control, lower blood pressure and lipids and help weight, sleep apnoea and joint pain. For many patients, \u00ab\u00a0better control with fewer medicines\u00a0\u00bb is a meaningful goal even without remission. Discuss realistic objectives with your diabetologist.<\/p>\n<h3>What about complications that already exist?<\/h3>\n<p>Advanced kidney disease, heart disease or severe eye disease do not exclude surgery, but they increase the risk and require careful assessment. Diabetic eye disease can temporarily worsen when blood sugar falls very quickly, a phenomenon also seen with intensive medical treatment, so an eye examination before surgery and close monitoring afterwards are recommended if you have retinopathy.<\/p>\n<h2 id=\"criteria\">Eligibility: international and Swiss criteria<\/h2>\n<h3>What do international guidelines recommend?<\/h3>\n<p>The second Diabetes Surgery Summit (DSS-II), whose recommendations were published in 2016 and endorsed by 45 medical and scientific societies, recommends metabolic surgery for people with type 2 diabetes and a BMI of 40 or more, and for those with a BMI of 35 to 39.9 when blood sugar is inadequately controlled despite lifestyle measures and optimal medical therapy. Surgery should also be considered with a BMI of 30 to 34.9 when control remains inadequate despite optimal oral or injectable treatment. These thresholds are lowered by 2.5 points for people of Asian origin. The 2022 joint guidelines of the ASMBS and the International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO) recommend surgery from a BMI of 35 regardless of other conditions and suggest considering it from 30 in people with metabolic disease.<\/p>\n<h3>What are the Swiss rules?<\/h3>\n<p>In Switzerland, basic insurance follows the KLV and the SMOB guidelines, not the international recommendations. The standard conditions are a BMI of 35 or more, two years of adequate weight-reduction treatment that did not achieve and maintain a BMI below 35, an assessment by an interdisciplinary team and surgery in a recognised centre, or with the insurer&rsquo;s specific prior approval elsewhere. The SMOB guidelines, in force since 1 July 2023, also allow metabolic surgery for type 2 diabetes that is difficult to control with a BMI between 30 and 35, if an HbA1c below 8% cannot be reached over at least twelve months despite optimal treatment by an endocrinologist and a qualified dietitian, and if the indication is made jointly with the endocrinologist. These operations are performed in reference centres.<\/p>\n<table>\n<thead>\n<tr>\n<th>BMI<\/th>\n<th>DSS-II (2016)<\/th>\n<th>ASMBS\/IFSO (2022)<\/th>\n<th>Switzerland (KLV and SMOB)<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>40 or more<\/td>\n<td>Recommended<\/td>\n<td>Recommended<\/td>\n<td>Covered if the general conditions are met<\/td>\n<\/tr>\n<tr>\n<td>35 to 39.9<\/td>\n<td>Recommended if diabetes is inadequately controlled<\/td>\n<td>Recommended regardless of comorbidity<\/td>\n<td>Covered if the general conditions are met<\/td>\n<\/tr>\n<tr>\n<td>30 to 34.9<\/td>\n<td>Consider if control is inadequate despite optimal treatment<\/td>\n<td>Consider with metabolic disease<\/td>\n<td>Narrow exception: HbA1c 8% or more for 12 months despite optimal specialist care; joint indication; reference centre<\/td>\n<\/tr>\n<tr>\n<td>Below 30<\/td>\n<td>Not recommended<\/td>\n<td>Not generally recommended<\/td>\n<td>Not covered<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h3>What documents should I gather?<\/h3>\n<ul>\n<li>Your BMI history and the record of weight-loss treatments over at least two years (dietitian visits, medicines, programmes).<\/li>\n<li>HbA1c values over time and the list of diabetes medicines with doses.<\/li>\n<li>Reports from your diabetologist or endocrinologist.<\/li>\n<li>Recent eye, kidney and heart assessments, if available.<\/li>\n<li>Any previous psychological assessment.<\/li>\n<\/ul>\n<p>Expats who have recently moved to Switzerland should bring records from previous countries, translated if needed, and ask the centre early whether documented treatment abroad can be taken into account.<\/p>\n<p><strong>Want to know your options?<\/strong> Ask for a <a href=\"https:\/\/www.medespoir.ch\/devis.php\">free, personalised quote<\/a> with your medical summary. It is sent within 48 hours, without commitment, and tells you whether surgery can be considered and under which conditions.<\/p>\n<h2 id=\"operation\">Sleeve or bypass when you have diabetes<\/h2>\n<h3>Which operation is better for diabetes?<\/h3>\n<p>Both improve diabetes. In randomised trials, the gastric bypass tends to give slightly higher remission rates and more weight loss, but the differences are modest and not always significant. In STAMPEDE, remission by the trial&rsquo;s definition was 29% after bypass and 23% after sleeve at five years; in SLEEVEPASS, 45% and 37%. The choice depends on other factors as much as on diabetes.<\/p>\n<h3>Which other factors guide the choice?<\/h3>\n<table>\n<thead>\n<tr>\n<th>Factor<\/th>\n<th>Often favours bypass<\/th>\n<th>Often favours sleeve<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>Reflux or hiatus hernia<\/td>\n<td>Yes: reflux usually improves<\/td>\n<td>Reflux may worsen<\/td>\n<\/tr>\n<tr>\n<td>Long-standing diabetes, high HbA1c<\/td>\n<td>Often preferred by surgeons<\/td>\n<td>Still effective<\/td>\n<\/tr>\n<tr>\n<td>Many regular medicines that must be well absorbed<\/td>\n<td>Absorption can change<\/td>\n<td>Less effect on absorption<\/td>\n<\/tr>\n<tr>\n<td>Anaemia, inflammatory bowel disease<\/td>\n<td>More risk of deficiencies<\/td>\n<td>Often preferred<\/td>\n<\/tr>\n<tr>\n<td>Need for endoscopic access to the bile ducts later<\/td>\n<td>More difficult<\/td>\n<td>Easier<\/td>\n<\/tr>\n<tr>\n<td>Risk of hypoglycaemia after meals<\/td>\n<td>More frequent<\/td>\n<td>Less frequent<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h3>What about the mini-bypass and other operations?<\/h3>\n<p>The one-anastomosis gastric bypass is popular in some countries, but the SMOB still classes it as a procedure in evaluation, to be performed in Switzerland within approved studies. More malabsorptive operations, such as the duodenal switch, produce high remission rates but more deficiencies and are reserved for specific situations in reference centres.<\/p>\n<h2 id=\"before\">Before surgery: tests and medicines<\/h2>\n<h3>Which tests are done before surgery?<\/h3>\n<p>Beyond the usual bariatric assessment (blood tests, nutritional status, psychological evaluation, sometimes a gastroscopy and a sleep apnoea test), people with diabetes need a recent HbA1c, kidney function and urine albumin, an eye examination, and often a heart assessment, especially if they have had diabetes for many years, high blood pressure or chest symptoms.<\/p>\n<h3>Should my blood sugar be optimised before surgery?<\/h3>\n<p>Yes. Poorly controlled diabetes increases the risk of infection and wound complications. Many teams aim to improve control before the operation, sometimes with a short pre-operative diet that also shrinks the liver and makes the operation easier. The pre-operative diet often lowers blood sugar quickly, so insulin and sulfonylurea doses may need to be reduced during that phase to avoid hypoglycaemia.<\/p>\n<h3>What happens to my diabetes medicines before the operation?<\/h3>\n<p>Your team gives you a written plan. The general principles are as follows, but only your doctors can apply them to you:<\/p>\n<ul>\n<li><strong>SGLT2 inhibitors<\/strong> (such as empagliflozin or dapagliflozin): international guidelines recommend stopping them three to four days before surgery, because, combined with fasting and a low-calorie diet, they can cause a form of ketoacidosis with near-normal blood sugar that is easy to miss.<\/li>\n<li><strong>GLP-1 receptor agonists and tirzepatide:<\/strong> they slow stomach emptying. Multi-society guidance published in October 2024 by the American Society of Anesthesiologists and partner societies says most patients can continue them, but higher-risk patients may need a liquid diet for 24 hours before surgery or other precautions. Your anaesthetist decides.<\/li>\n<li><strong>Insulin:<\/strong> doses are usually reduced on the day before and the day of surgery, according to a specific plan.<\/li>\n<li><strong>Sulfonylureas<\/strong> (such as gliclazide): often stopped or reduced because of the risk of hypoglycaemia when eating little.<\/li>\n<li><strong>Metformin:<\/strong> usually paused around the operation and restarted according to kidney function and intake.<\/li>\n<\/ul>\n<h2 id=\"after\">After surgery: glucose monitoring and medicines<\/h2>\n<p>The weeks after surgery are when diabetes management changes most, and when the risk of both high and low blood sugar must be watched.<\/p>\n<h3>How is blood sugar monitored in hospital?<\/h3>\n<p>Capillary glucose is checked several times a day after surgery, and insulin is given as needed. Many patients need much less insulin than before, sometimes none, already in the first days. The team adjusts treatment before discharge and gives you a plan for the following weeks.<\/p>\n<h3>Which medicines are usually stopped or reduced after surgery?<\/h3>\n<p>Medicines that can cause hypoglycaemia, such as sulfonylureas and high insulin doses, are generally stopped or strongly reduced. SGLT2 inhibitors are often not restarted in the first weeks, while food intake is very low, because of the ketoacidosis risk. Metformin is often continued or restarted if blood sugar requires it, in a form your team considers suitable after surgery. GLP-1 medicines are usually paused after surgery. The goal is to avoid hypoglycaemia while keeping blood sugar in a safe range; the plan is revised at each follow-up visit.<\/p>\n<h3>How often should I check my glucose at home?<\/h3>\n<p>Your team tells you how often, especially if you still take insulin or another medicine that can cause hypoglycaemia. Continuous glucose monitoring sensors can be useful in the first months and in people with symptoms of low blood sugar. Write down readings, meals and symptoms and bring them to each visit.<\/p>\n<h3>Which targets apply after surgery?<\/h3>\n<p>Targets are individual. Before surgery, the usual HbA1c target for many adults is around 7% (53 mmol\/mol); after surgery, many patients go well below it without medicines. The priority in the first months is to avoid hypoglycaemia while medicines are being reduced.<\/p>\n<h3>What about my blood pressure and cholesterol medicines?<\/h3>\n<p>Blood pressure often falls with weight loss, and some patients become dizzy if they continue the same doses. Report dizziness and check your blood pressure at home. Cholesterol medicines are usually continued and reassessed later; their benefit for heart protection does not depend only on weight.<\/p>\n<h3>Can I take my tablets normally after surgery?<\/h3>\n<p>In the first weeks, large tablets may be difficult to swallow, and some extended-release forms are not suitable after a bypass. Ask your team or pharmacist which medicines should be crushed, replaced by liquid forms or changed. Anti-inflammatory painkillers are generally avoided after a bypass because of the risk of ulcers.<\/p>\n<h2 id=\"hypo\">Low blood sugar after a bypass<\/h2>\n<p>A lesser-known side of metabolic surgery is post-bariatric hypoglycaemia: low blood sugar that occurs one to three hours after meals, mostly after a gastric bypass, sometimes after a sleeve, usually starting months or years after the operation.<\/p>\n<h3>Why does it happen?<\/h3>\n<p>After a bypass, sugar from a meal reaches the intestine and the blood very quickly, triggering a strong release of insulin, amplified by gut hormones. Blood sugar then falls below normal. This is sometimes called \u00ab\u00a0late dumping\u00a0\u00bb. It is different from early dumping, which occurs within 30 minutes of eating and causes cramps, diarrhoea and a racing heart.<\/p>\n<h3>How common is it?<\/h3>\n<p>Estimates vary widely depending on how it is measured. A 2023 review in <em>Diabetes\/Metabolism Research and Reviews<\/em> reported that low post-meal glucose may be detected in up to 88% of people after bariatric surgery with some diagnostic tools, often without symptoms. Severe, symptomatic forms are much less common, but they matter because they can cause confusion, falls or loss of consciousness.<\/p>\n<h3>What are the symptoms?<\/h3>\n<p>Sweating, trembling, hunger, palpitations, anxiety, weakness, blurred vision or difficulty concentrating, typically one to three hours after a meal rich in fast sugars. If you still have diabetes medicines, distinguishing these symptoms from medicine-induced hypoglycaemia is essential.<\/p>\n<h3>How is it managed?<\/h3>\n<ul>\n<li>Avoid fast sugars and sweet drinks; favour protein, fibre and complex carbohydrates in small, regular meals.<\/li>\n<li>Do not drink with meals; wait about 30 minutes.<\/li>\n<li>Carry a source of glucose and treat a low reading as instructed by your team.<\/li>\n<li>Report episodes to your team: medicines can be used if diet is not enough, and rare severe cases need specialised treatment.<\/li>\n<\/ul>\n<h3>Can I drive with this kind of hypoglycaemia?<\/h3>\n<p>Hypoglycaemia affects driving ability. If you have had episodes, discuss driving safety with your doctor, check your glucose before driving if advised, and never drive while you have symptoms.<\/p>\n<h2 id=\"everyday\">Everyday questions in the first year<\/h2>\n<h3>What should I do if I am ill, vomiting or cannot eat?<\/h3>\n<p>Ask your team in advance for \u00ab\u00a0sick-day rules\u00a0\u00bb. When you cannot eat or drink normally, some diabetes medicines can become dangerous: those that cause hypoglycaemia, and SGLT2 inhibitors and metformin, which may need to be paused when you are dehydrated. Drink small sips of fluid regularly, check your glucose more often if you still take medicines, and contact your team or an emergency service if vomiting persists for more than a day, if you cannot keep fluids down or if you feel confused. Persistent vomiting after bariatric surgery always needs medical attention, regardless of diabetes.<\/p>\n<h3>Can I drink alcohol?<\/h3>\n<p>After a bypass, alcohol reaches the blood faster and in higher concentrations, and the risk of problem drinking increases over the years. Alcohol can also cause hypoglycaemia, particularly if you still take insulin or a sulfonylurea, or if you have post-bariatric hypoglycaemia. Most teams advise avoiding alcohol in the first months and remaining very moderate afterwards, never on an empty stomach.<\/p>\n<h3>Does exercise change my glucose management?<\/h3>\n<p>Regular activity improves insulin sensitivity and helps keep weight off, which supports remission. If you still take insulin or a sulfonylurea, exercise can lower blood sugar further, so check your glucose before and after longer sessions and carry a quick source of glucose. Muscle strengthening is especially valuable after surgery, to limit the loss of muscle that accompanies rapid weight loss.<\/p>\n<h3>What about travel and time zones?<\/h3>\n<p>If you still take insulin or other medicines, carry them in your hand luggage with a medical certificate, plan doses with your doctor when crossing time zones, and bring your glucose meter or sensor and supplies. Take your vitamin supplements with you, and protein snacks that suit your new eating pattern.<\/p>\n<h3>Can I become pregnant after metabolic surgery?<\/h3>\n<p>Yes, and fertility often improves with weight loss. Most teams advise waiting 12 to 18 months after surgery, until weight is stable, and using reliable contraception in the meantime, preferably not only the pill, whose absorption may be less reliable after some operations. Screening for gestational diabetes needs adapting: the usual sugary drink test can cause dumping after a bypass, so teams use other methods, such as glucose monitoring. Plan any pregnancy with your bariatric team and your gynaecologist, and check your vitamins beforehand.<\/p>\n<h3>Do I still need my diabetes nurse and dietitian?<\/h3>\n<p>Yes. Dietitians help you build an eating pattern that protects both your glucose and your nutrition, and diabetes educators help you adjust medicines safely. In Switzerland, nutritional counselling prescribed by a doctor for diabetes or obesity is covered by basic insurance under conditions, which your doctor can confirm.<\/p>\n<h2 id=\"longterm\">Follow-up for life and the risk of relapse<\/h2>\n<h3>Can diabetes come back after surgery?<\/h3>\n<p>Yes. In the Swedish Obese Subjects study, the share of surgical patients in remission fell from 72.3% at two years to 30.4% at fifteen years; in ARMMS-T2D, from 18.2% at seven years to 12.7% at twelve years. Relapse is more likely with weight regain, long-standing diabetes before surgery and progressive decline of insulin production. Even after a relapse, control is often easier than before surgery.<\/p>\n<h3>Which check-ups do I need?<\/h3>\n<table>\n<thead>\n<tr>\n<th>Check<\/th>\n<th>Usual rhythm<\/th>\n<th>Why<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>HbA1c<\/td>\n<td>Every 3 to 6 months in the first years, then at least once a year even in remission<\/td>\n<td>Detect relapse early<\/td>\n<\/tr>\n<tr>\n<td>Eye examination<\/td>\n<td>As recommended by your ophthalmologist, continued after surgery<\/td>\n<td>Retinopathy does not disappear with remission<\/td>\n<\/tr>\n<tr>\n<td>Kidney function and urine albumin<\/td>\n<td>At least yearly<\/td>\n<td>Monitor diabetic kidney disease<\/td>\n<\/tr>\n<tr>\n<td>Foot examination<\/td>\n<td>At least yearly, more often if nerves are affected<\/td>\n<td>Prevent ulcers<\/td>\n<\/tr>\n<tr>\n<td>Vitamins and minerals (iron, B12, folate, vitamin D, calcium, others)<\/td>\n<td>According to the operation and the SMOB follow-up plan<\/td>\n<td>Deficiencies are common after surgery<\/td>\n<\/tr>\n<tr>\n<td>Weight, blood pressure, lipids<\/td>\n<td>At each visit<\/td>\n<td>Cardiovascular protection<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h3>Who organises the follow-up in Switzerland?<\/h3>\n<p>The SMOB requires written consent to lifelong follow-up, organised by the bariatric centre in the first years and then often shared with the family doctor and the diabetologist. If you move canton or country, make sure your records follow you.<\/p>\n<h3>What helps keep diabetes in remission?<\/h3>\n<p>Maintaining weight loss is the key factor. Regular physical activity, including muscle strengthening, an eating pattern rich in protein and vegetables, limited alcohol and attendance at follow-up visits all help. Some patients with weight regain or diabetes relapse benefit from medicines, including GLP-1 medicines, as an addition to surgery; reimbursement after bariatric surgery is not part of the standard conditions summarised by the University Hospital Zurich, so your doctor should check with your insurer.<\/p>\n<h2 id=\"glp1\">GLP-1 medicines or surgery?<\/h2>\n<h3>Can Wegovy or Mounjaro replace surgery for diabetes?<\/h3>\n<p>For some patients, yes, at least for a time. These medicines lower blood sugar and weight substantially. Their effect lasts as long as they are taken, and weight usually returns after stopping. In routine practice, many patients stop for reasons of side effects, cost or supply. Surgery produces larger and more durable weight loss on average, with surgical risks and lifelong supplements. The new Swiss guidance encourages discussing both as steps in one pathway rather than as rivals.<\/p>\n<h3>How do they compare in practice?<\/h3>\n<table>\n<thead>\n<tr>\n<th>Criterion<\/th>\n<th>GLP-1 medicines (semaglutide, tirzepatide)<\/th>\n<th>Metabolic surgery (sleeve, bypass)<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>Swiss reimbursement for weight management<\/td>\n<td>BMI above 35, or above 28 with diabetes or another condition; specialist prescription; initially three years<\/td>\n<td>BMI 35 or more after two years of failed treatment; narrow exception 30 to 35 for diabetes<\/td>\n<\/tr>\n<tr>\n<td>Effect on blood sugar<\/td>\n<td>Strong while the medicine is taken<\/td>\n<td>Strong and often rapid; remission possible<\/td>\n<\/tr>\n<tr>\n<td>Duration<\/td>\n<td>Ongoing treatment<\/td>\n<td>Permanent change, with risk of relapse over years<\/td>\n<\/tr>\n<tr>\n<td>Main risks<\/td>\n<td>Nausea, vomiting, constipation; rarer serious effects<\/td>\n<td>Surgical complications, deficiencies, reflux (sleeve), dumping and hypoglycaemia (bypass)<\/td>\n<\/tr>\n<tr>\n<td>Follow-up<\/td>\n<td>Regular prescriptions and monitoring<\/td>\n<td>Lifelong follow-up and supplements<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h3>Should I try medicines first?<\/h3>\n<p>Many teams now discuss medicines before surgery, particularly with a BMI between 35 and 40 or when surgery is hesitated. For people with very high BMI, long-standing poorly controlled diabetes or multiple complications, surgery may be the more effective option. The decision is individual and shared between you, your diabetologist and the surgical team.<\/p>\n<h2 id=\"abroad\">Insurance, Switzerland or abroad<\/h2>\n<p>For people with diabetes, the question of where to have surgery has a specific dimension: if you meet the Swiss criteria, basic insurance pays for the operation in Switzerland, and your diabetes care is already organised here.<\/p>\n<h3>Does basic insurance pay for metabolic surgery?<\/h3>\n<p>Yes, when the KLV and SMOB conditions are met, in a recognised centre or with the insurer&rsquo;s prior approval. You still pay your deductible and co-payment. Follow-up visits, blood tests and treatment of complications are covered like other medical care.<\/p>\n<h3>Why do some people still consider surgery abroad?<\/h3>\n<p>Usually because they do not meet the Swiss criteria, for example a BMI just below the threshold or less than two years of documented treatment, or because of waiting times. Planned surgery abroad is not covered by basic insurance, so the operation is paid privately. The follow-up after your return, including diabetes management, then takes place in Switzerland with your family doctor or diabetologist.<\/p>\n<h3>What should I check before choosing a centre abroad?<\/h3>\n<ul>\n<li>That the team assesses your diabetes properly: HbA1c, complications, medicines, eye examination.<\/li>\n<li>That you leave with a written plan for your diabetes medicines and glucose checks.<\/li>\n<li>That your Swiss doctor agrees to take over the follow-up, and has the operative report.<\/li>\n<li>Which vitamins and supplements to take, and which blood tests to plan.<\/li>\n<li>Who to contact in case of a complication after your return.<\/li>\n<\/ul>\n<h3>What does Medespoir offer?<\/h3>\n<p>Medespoir offers sleeve gastrectomy and gastric bypass in its clinics in Tunisia, described on its French-language pages on <a href=\"https:\/\/www.medespoir.ch\/sleeve.php\">sleeve gastrectomy<\/a>, <a href=\"https:\/\/www.medespoir.ch\/bypass.php\">gastric bypass<\/a> and in its <a href=\"https:\/\/www.medespoir.ch\/guide-chirurgie-obesite.php\">obesity surgery guide<\/a>. Treatment in Tunisia is significantly cheaper than in Switzerland; the exact price is given in a free, personalised quote. The Tunisian package includes the pre-operative consultation, tests, the operation with the full team, the hospital stay, the operative report, full-board hotel accommodation for you and one companion, transfers and remote follow-up after your return. Flights, personal expenses, care in Switzerland after your return, travel insurance (recommended) and bank charges are not included. Consultation and medical documents are in French. For Turkey, the quote specifies whether the procedure is possible and where.<\/p>\n<h3>Is surgery abroad a good idea if I have complicated diabetes?<\/h3>\n<p>The more complex your diabetes, the more important continuity of care becomes. With advanced kidney or heart disease, insulin-treated diabetes with frequent hypoglycaemia or severe eye disease, surgery in a Swiss reference centre, close to your diabetologist, is usually the safer choice, and the SMOB requires reference centres for complex cases. If your diabetes is recent, well documented and your Swiss doctor is ready to manage your medicines afterwards, the situation is simpler.<\/p>\n<h2 id=\"faq\">FAQ<\/h2>\n<h3>Can bariatric surgery put type 2 diabetes into remission?<\/h3>\n<p>Yes, in a significant share of patients, especially with recent diabetes and no insulin treatment. Remission is defined as an HbA1c below 6.5% at least three months after stopping medicines.<\/p>\n<h3>Is remission permanent?<\/h3>\n<p>Not always. Diabetes returns in some patients over the years, particularly with weight regain. Yearly HbA1c checks are recommended even in remission.<\/p>\n<h3>Which operation is best for diabetes?<\/h3>\n<p>Both the sleeve and the bypass improve diabetes. The bypass tends to give slightly higher remission rates and helps reflux; the sleeve causes fewer deficiencies and less hypoglycaemia.<\/p>\n<h3>Can I have surgery with a BMI of 32 and diabetes in Switzerland?<\/h3>\n<p>Only exceptionally: the SMOB allows it when HbA1c stays at 8% or above for twelve months despite optimal care by an endocrinologist and a dietitian, with a joint indication and surgery in a reference centre.<\/p>\n<h3>Do I stop my diabetes medicines after surgery?<\/h3>\n<p>Many are reduced or stopped, but only according to your team&rsquo;s plan. Never stop insulin or other medicines on your own.<\/p>\n<h3>Why must SGLT2 inhibitors be stopped before surgery?<\/h3>\n<p>Because, combined with fasting, they can cause ketoacidosis with near-normal blood sugar. Guidelines recommend stopping them three to four days before.<\/p>\n<h3>What is post-bariatric hypoglycaemia?<\/h3>\n<p>Low blood sugar one to three hours after meals, mostly after a bypass. Diet changes usually help; report symptoms to your team.<\/p>\n<h3>Do I still need eye examinations if I am in remission?<\/h3>\n<p>Yes. Existing damage does not disappear, and diabetic eye disease must be monitored.<\/p>\n<h3>Will insurance pay for Mounjaro if my diabetes returns after surgery?<\/h3>\n<p>For weight management after bariatric surgery, not under the standard conditions. Prescription for diabetes follows different rules; ask your doctor to check with your insurer.<\/p>\n<p><strong>Your next step:<\/strong> request a <a href=\"https:\/\/www.medespoir.ch\/devis.php\">free, personalised quote<\/a> for metabolic surgery, sent within 48 hours. Treatment in Tunisia is significantly cheaper than in Switzerland, and your medical file is reviewed before any proposal.<\/p>\n<p><strong>Main sources:<\/strong> <a href=\"https:\/\/doi.org\/10.2337\/dci21-0034\" target=\"_blank\" rel=\"noopener\">Riddle MC et al., consensus report on remission in type 2 diabetes, Diabetes Care (2021)<\/a>; <a href=\"https:\/\/doi.org\/10.1056\/NEJMoa1600869\" target=\"_blank\" rel=\"noopener\">Schauer PR et al., STAMPEDE 5-year outcomes, NEJM (2017)<\/a>; <a href=\"https:\/\/doi.org\/10.1001\/jama.2024.0318\" target=\"_blank\" rel=\"noopener\">Courcoulas AP et al., ARMMS-T2D, JAMA (27 February 2024)<\/a>; <a href=\"https:\/\/doi.org\/10.1001\/jama.2014.5988\" target=\"_blank\" rel=\"noopener\">Sj\u00f6str\u00f6m L et al., Swedish Obese Subjects, JAMA (2014)<\/a>; <a href=\"https:\/\/doi.org\/10.1001\/jama.2017.20313\" target=\"_blank\" rel=\"noopener\">Salminen P et al., SLEEVEPASS, JAMA (2018)<\/a>; <a href=\"https:\/\/doi.org\/10.1001\/jama.2017.20897\" target=\"_blank\" rel=\"noopener\">Peterli R et al., SM-BOSS, JAMA (2018)<\/a>; <a href=\"https:\/\/doi.org\/10.1016\/j.soard.2016.05.018\" target=\"_blank\" rel=\"noopener\">Rubino F et al., DSS-II recommendations (2016)<\/a>; <a href=\"https:\/\/doi.org\/10.1007\/s11695-022-06332-1\" target=\"_blank\" rel=\"noopener\">Eisenberg D et al., ASMBS\/IFSO indications (2022)<\/a>; <a href=\"https:\/\/doi.org\/10.1016\/S2213-8587(13)70070-6\" target=\"_blank\" rel=\"noopener\">Still CD et al., DiaRem score (2014)<\/a>; <a href=\"https:\/\/doi.org\/10.1002\/dmrr.3750\" target=\"_blank\" rel=\"noopener\">Rossini G et al., post-bariatric hypoglycaemia (2023)<\/a>; <a href=\"https:\/\/www.smob.ch\/guidelines-for-the-surgical-treatment-of-obesity\/\" target=\"_blank\" rel=\"noopener\">SMOB, guidelines (1 July 2023)<\/a>; <a href=\"https:\/\/smw.ch\/index.php\/smw\/article\/view\/5415\" target=\"_blank\" rel=\"noopener\">Gerber PA et al., Swiss obesity clinical practice guidance, Swiss Medical Weekly (19 May 2026)<\/a>; <a href=\"https:\/\/svde-asdd.ch\/wp-content\/uploads\/2026\/02\/2026_01_28_Positionspapier-Wegovy-Mounjaro.pdf\" target=\"_blank\" rel=\"noopener\">SVDE and ALLOB, position paper on Wegovy and Mounjaro (31 January 2026, in German)<\/a>; <a href=\"https:\/\/www.usz.ch\/en\/?p=235852\" target=\"_blank\" rel=\"noopener\">University Hospital Zurich, drug therapy for obesity (updated 22 October 2026)<\/a>; <a href=\"https:\/\/www.emjreviews.com\/diabetes\/news\/sleeve-gastrectomy-more-effective-than-glp-1-drugs-for-weight-loss\/\" target=\"_blank\" rel=\"noopener\">EMJ, report on Leslie D et al. (2026)<\/a>; <a href=\"https:\/\/asahq.org\/about-asa\/newsroom\/news-releases\/2024\/10\/new-multi-society-glp-1-guidance\" target=\"_blank\" rel=\"noopener\">ASA, multi-society GLP-1 guidance (October 2024)<\/a>.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Remission, long-term trial results, Swiss and international eligibility criteria, sleeve or bypass, medicines and glucose monitoring around surgery, low blood sugar after a bypass and lifelong follow-up.<\/p>\n","protected":false},"author":1,"featured_media":12110,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[285],"tags":[],"class_list":["post-11988","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-switzerland"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Metabolic Surgery for Diabetes in Switzerland: Remission<\/title>\n<meta name=\"description\" content=\"Metabolic surgery for type 2 diabetes in Switzerland: remission, SMOB criteria, sleeve or bypass, medicines, glucose checks and follow-up.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.medespoir.ch\/blog\/type-2-diabetes-metabolic-surgery-switzerland\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Metabolic Surgery for Diabetes in Switzerland: Remission\" \/>\n<meta property=\"og:description\" content=\"Metabolic surgery for type 2 diabetes in Switzerland: remission, SMOB criteria, sleeve or bypass, medicines, glucose checks and follow-up.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.medespoir.ch\/blog\/type-2-diabetes-metabolic-surgery-switzerland\/\" \/>\n<meta property=\"og:site_name\" content=\"Actualit\u00e9s\" \/>\n<meta property=\"article:published_time\" content=\"2026-11-09T09:00:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.medespoir.ch\/blog\/wp-content\/uploads\/2026\/11\/type-2-diabetes-metabolic-surgery-switzerland-unsplash.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1600\" \/>\n\t<meta property=\"og:image:height\" content=\"1067\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Espoir\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"Espoir\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"27 minutes\" \/>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Metabolic Surgery for Diabetes in Switzerland: Remission","description":"Metabolic surgery for type 2 diabetes in Switzerland: remission, SMOB criteria, sleeve or bypass, medicines, glucose checks and follow-up.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.medespoir.ch\/blog\/type-2-diabetes-metabolic-surgery-switzerland\/","og_locale":"fr_FR","og_type":"article","og_title":"Metabolic Surgery for Diabetes in Switzerland: Remission","og_description":"Metabolic surgery for type 2 diabetes in Switzerland: remission, SMOB criteria, sleeve or bypass, medicines, glucose checks and follow-up.","og_url":"https:\/\/www.medespoir.ch\/blog\/type-2-diabetes-metabolic-surgery-switzerland\/","og_site_name":"Actualit\u00e9s","article_published_time":"2026-11-09T09:00:00+00:00","og_image":[{"width":1600,"height":1067,"url":"https:\/\/www.medespoir.ch\/blog\/wp-content\/uploads\/2026\/11\/type-2-diabetes-metabolic-surgery-switzerland-unsplash.jpg","type":"image\/jpeg"}],"author":"Espoir","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"Espoir","Dur\u00e9e de lecture estim\u00e9e":"27 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.medespoir.ch\/blog\/type-2-diabetes-metabolic-surgery-switzerland\/#article","isPartOf":{"@id":"https:\/\/www.medespoir.ch\/blog\/type-2-diabetes-metabolic-surgery-switzerland\/"},"author":{"name":"Espoir","@id":"https:\/\/www.medespoir.ch\/blog\/#\/schema\/person\/47b0a812ba344021f9fc48cd9d67e745"},"headline":"Type 2 diabetes and weight-loss surgery in Switzerland: can metabolic surgery bring remission?","datePublished":"2026-11-09T09:00:00+00:00","mainEntityOfPage":{"@id":"https:\/\/www.medespoir.ch\/blog\/type-2-diabetes-metabolic-surgery-switzerland\/"},"wordCount":5459,"image":{"@id":"https:\/\/www.medespoir.ch\/blog\/type-2-diabetes-metabolic-surgery-switzerland\/#primaryimage"},"thumbnailUrl":"https:\/\/www.medespoir.ch\/blog\/wp-content\/uploads\/2026\/11\/type-2-diabetes-metabolic-surgery-switzerland-unsplash.jpg","articleSection":["Switzerland"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/www.medespoir.ch\/blog\/type-2-diabetes-metabolic-surgery-switzerland\/","url":"https:\/\/www.medespoir.ch\/blog\/type-2-diabetes-metabolic-surgery-switzerland\/","name":"Metabolic Surgery for Diabetes in Switzerland: Remission","isPartOf":{"@id":"https:\/\/www.medespoir.ch\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.medespoir.ch\/blog\/type-2-diabetes-metabolic-surgery-switzerland\/#primaryimage"},"image":{"@id":"https:\/\/www.medespoir.ch\/blog\/type-2-diabetes-metabolic-surgery-switzerland\/#primaryimage"},"thumbnailUrl":"https:\/\/www.medespoir.ch\/blog\/wp-content\/uploads\/2026\/11\/type-2-diabetes-metabolic-surgery-switzerland-unsplash.jpg","datePublished":"2026-11-09T09:00:00+00:00","author":{"@id":"https:\/\/www.medespoir.ch\/blog\/#\/schema\/person\/47b0a812ba344021f9fc48cd9d67e745"},"description":"Metabolic surgery for type 2 diabetes in Switzerland: remission, SMOB criteria, sleeve or bypass, medicines, glucose checks and follow-up.","breadcrumb":{"@id":"https:\/\/www.medespoir.ch\/blog\/type-2-diabetes-metabolic-surgery-switzerland\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.medespoir.ch\/blog\/type-2-diabetes-metabolic-surgery-switzerland\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.medespoir.ch\/blog\/type-2-diabetes-metabolic-surgery-switzerland\/#primaryimage","url":"https:\/\/www.medespoir.ch\/blog\/wp-content\/uploads\/2026\/11\/type-2-diabetes-metabolic-surgery-switzerland-unsplash.jpg","contentUrl":"https:\/\/www.medespoir.ch\/blog\/wp-content\/uploads\/2026\/11\/type-2-diabetes-metabolic-surgery-switzerland-unsplash.jpg","width":1600,"height":1067,"caption":"Photo : Sweet Life \/ Unsplash"},{"@type":"BreadcrumbList","@id":"https:\/\/www.medespoir.ch\/blog\/type-2-diabetes-metabolic-surgery-switzerland\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/www.medespoir.ch\/blog\/"},{"@type":"ListItem","position":2,"name":"Type 2 diabetes and weight-loss surgery in Switzerland: can metabolic surgery bring remission?"}]},{"@type":"WebSite","@id":"https:\/\/www.medespoir.ch\/blog\/#website","url":"https:\/\/www.medespoir.ch\/blog\/","name":"Actualit\u00e9s","description":"tout ce qui est en rapport avec la chirurgie esth\u00e9tique","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.medespoir.ch\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Person","@id":"https:\/\/www.medespoir.ch\/blog\/#\/schema\/person\/47b0a812ba344021f9fc48cd9d67e745","name":"Espoir","image":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/secure.gravatar.com\/avatar\/f330532a629d52f3de6c9776e411456490900271ce14c41825d1e33fe293c4fc?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/f330532a629d52f3de6c9776e411456490900271ce14c41825d1e33fe293c4fc?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/f330532a629d52f3de6c9776e411456490900271ce14c41825d1e33fe293c4fc?s=96&d=mm&r=g","caption":"Espoir"},"sameAs":["http:\/\/www.medespoir.ch"],"url":"https:\/\/www.medespoir.ch\/blog\/author\/espoir\/"}]}},"_links":{"self":[{"href":"https:\/\/www.medespoir.ch\/blog\/wp-json\/wp\/v2\/posts\/11988","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.medespoir.ch\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.medespoir.ch\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.medespoir.ch\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.medespoir.ch\/blog\/wp-json\/wp\/v2\/comments?post=11988"}],"version-history":[{"count":1,"href":"https:\/\/www.medespoir.ch\/blog\/wp-json\/wp\/v2\/posts\/11988\/revisions"}],"predecessor-version":[{"id":12111,"href":"https:\/\/www.medespoir.ch\/blog\/wp-json\/wp\/v2\/posts\/11988\/revisions\/12111"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.medespoir.ch\/blog\/wp-json\/wp\/v2\/media\/12110"}],"wp:attachment":[{"href":"https:\/\/www.medespoir.ch\/blog\/wp-json\/wp\/v2\/media?parent=11988"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.medespoir.ch\/blog\/wp-json\/wp\/v2\/categories?post=11988"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.medespoir.ch\/blog\/wp-json\/wp\/v2\/tags?post=11988"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}